Terbutaline for sinus node dysfunction after heart transplantation Authors: Ersilia M. DeFilippis, William Tate, Alice Chung, Jose L. Batista, Jaya Batra, Matthew Regan, Youssef A. Elnabawi, Elena M. Donald, Elaine Y. Wan, Angelo Biviano, Geoffrey Rubin, David Majure, Farhana Latif, Koji Takeda, Kevin J. Clerkin, Gabriel Sayer, Nir Uriel, Hirad Yarmohammadi Published: 2026 ABSTRACT BackgroundEarly sinus node dysfunction (SND) occurs in 2%–4% of patients following heart transplantation (HT).ObjectiveThe purpose of the current study was to examine characteristics of patients requiring terbutaline for SND post-HT and clinical and hemodynamic outcomes.MethodsA retrospective study was conducted at 2 centers to identify HT recipients from January 2020 to June 2025 started on terbutaline for early SND. Data was collected regarding recipient and donor characteristics and compared between terbutaline and no terbutaline groups. For the terbutaline group, additional information was obtained regarding changes in hemodynamics, dosing, and tolerability. Response to terbutaline after steady-state dosing and sinus node recovery were assessed.Results450 individuals underwent bicaval HT (median age 56 years, 75% male, 23% black, 18% Hispanic). Of these, 30 (6.7%) were initiated on terbutaline an average of 7 days post-HT. Demographics, pre-transplant mechanical circulatory support, or pre-transplant amiodarone exposure were similar between groups. Older donor age, longer ischemic time, and Organ Care System use were significantly associated with terbutaline use. Heart rate and cardiac index by Fick significantly increased after starting terbutaline with significant individual variability. 50% were classified as having sinus node recovery; 2 patients ultimately needed a permanent pacemaker.ConclusionDespite individual variability in heart rate response with terbutaline, early SND was able to be managed pharmacologically in most patients and need for permanent pacemaker remained low. Key Findings ▪In this single-center study, less than 10% of heart transplant recipients required initiation of terbutaline for early sinus node dysfunction post-operatively.▪Among those started on terbutaline, there was a significant increase in heart rate and Fick cardiac index after treatment initiation although changes varied widely from individual to individual.▪50% of those initiated on terbutaline had sinus node recovery defined as heart rate of at least 90 beats per minute at drug discontinuation.▪Only 2 patients required permanent pacemaker implantation early after transplant. Key Findings ▪In this single-center study, less than 10% of heart transplant recipients required initiation of terbutaline for early sinus node dysfunction post-operatively.▪Among those started on terbutaline, there was a significant increase in heart rate and Fick cardiac index after treatment initiation although changes varied widely from individual to individual.▪50% of those initiated on terbutaline had sinus node recovery defined as heart rate of at least 90 beats per minute at drug discontinuation.▪Only 2 patients required permanent pacemaker implantation early after transplant. ▪In this single-center study, less than 10% of heart transplant recipients required initiation of terbutaline for early sinus node dysfunction post-operatively. In this single-center study, less than 10% of heart transplant recipients required initiation of terbutaline for early sinus node dysfunction post-operatively. ▪Among those started on terbutaline, there was a significant increase in heart rate and Fick cardiac index after treatment initiation although changes varied widely from individual to individual. Among those started on terbutaline, there was a significant increase in heart rate and Fick cardiac index after treatment initiation although changes varied widely from individual to individual. ▪50% of those initiated on terbutaline had sinus node recovery defined as heart rate of at least 90 beats per minute at drug discontinuation. 50% of those initiated on terbutaline had sinus node recovery defined as heart rate of at least 90 beats per minute at drug discontinuation. ▪Only 2 patients required permanent pacemaker implantation early after transplant. Only 2 patients required permanent pacemaker implantation early after transplant. Introduction Since the adoption of bicaval anastomosis as the preferred technique for heart transplantation (HT), the need for permanent pacemaker (PPM) implantation has markedly reduced; however, early sinus node dysfunction (SND) still occurs in 2%–4% of patients following HT.1, 2, 3 Although the definition of early SND varies in the literature, it is most commonly defined as relative sinus bradycardia, sinus arrest, or sinus pauses of >3 seconds occurring within 30 days after HT.1 Increasingly, it has been recognized that early SND is often transient, with approximately 70% of patients who receive a PPM for early SND being pacemaker-independent after long-term follow-up.4,5 Pharmacological therapies have been increasingly used to bridge patients through this transient phase.6,7 Isoproterenol, the most commonly employed agent, is limited by its requirement for intravenous administration in an intensive care setting.6 In contrast, terbutaline, an oral β2-adrenergic agonist, can be used as an alternative for the treatment of relative, symptomatic bradycardia secondary to early SND after HT. However, the available evidence supporting its use is scarce, limited to small single-center observational studies.8,9 Furthermore, data are lacking comparing characteristics of HT recipients who required terbutaline to those who did not and possible insights into which patients may have beneficial hemodynamic and clinical response. The purpose of the current study was to examine clinical characteristics of patients requiring terbutaline and clinical outcomes at 2 heart transplant centers. Methods Study population A retrospective study was conducted at 2 centers (Columbia University Irving Medical Center and Weill Cornell Medical Center) to identify HT recipients initiated on terbutaline during their index hospitalization for early SND and received at least 48 hours of the medication. In 2018, we modified our institutional approach to pacemaker implantation after HT whereby patients were managed more expectantly to try to delay insertion of permanent devices.7 Factors prompting initiation of terbutaline included a heart rate (HR) that remained consistently low (relative to expected tachycardia in a post-heart transplant patient) or persistent pacing requirements while weaning inotropes in the early post-operative period. Poor perfusion, such as hypotension, may have been present but is not required. Patients were included in this analysis if they were transplanted between January 2020 and June 2025. Patients started on terbutaline after discharge from their index admission were excluded from the current analysis given the focus on early conduction disease after HT. This study was approved by the Columbia University Irving Medical Center Institutional Review Board and informed consent was waived. The research reported in this paper adhered to Declaration of Helsinki guidelines. Data collection Data was collected on recipient demographics including age, sex, race, ethnicity, etiology of heart failure (HF), pre-transplant temporary and durable mechanical circulatory support (MCS), and use of amiodarone pre-transplant. Use of amiodarone pre-transplant was defined by receiving daily maintenance amiodarone therapy within 1 month of transplant and/or a positive amiodarone level, laboratory values that are commonly checked as part of pre-operative testing immediately prior to HT at our institution. Donor characteristics were collected including donor sex and age. Additionally, data regarding primary graft dysfunction (PGD), need for renal replacement therapy and intensive care unit (ICU) length of stay was collected. For patients initiated on terbutaline, additional data was extracted regarding start date, starting and maximum dose, potassium levels, renal function, and changes in HR over time. HR was determined by electrocardiograms which are performed daily in the inpatient setting early post-HT, as these were most likely to reflect the underlying rhythm particularly in patients who were otherwise pacer-dependent. Additionally, hemodynamics including systolic and mean pulmonary artery (PA) pressures, right atrial (RA) pressure and cardiac index by Fick were collected prior to and following drug initiation. As many patients had terbutaline initiated in the ICU with concomitant use of inotropes, hemodynamics were collected from indwelling Swan-Ganz catheter. The need for pacemaker between HT and last follow-up was collected and mortality. Follow-up data was collected through September 2025. Response to terbutaline Patients were classified as responders and non-responders to terbutaline based on change in HR from day 0 (pre-drug start) and day 3 (after 5 half-lives of the medication). Response was defined as an increase in HR by at least 15 beats per minute (bpm) at day 3.10 Sinus node recovery Recognizing that some patients will have improvement in HR independent of terbutaline use, sinus node recovery was defined by HR of 90 bpm at drug discontinuation.7 Data were also collected on patients who required PPM. Statistical analysis Categorical variables were represented as frequency and proportion. Continuous variables were represented as median and interquartile range (IQR). Baseline characteristics were compared between patients initiated on terbutaline and those who were not. Categorical variables were analyzed using χ2 tests; Fisher’s exact test was applied when expected cell counts were <5 in 2 × 2 tables, and Monte Carlo simulation was used for larger contingency tables. Paired Student’s t test was used for continuous variables. When comparing changes pre- and post-terbutaline, a paired Student’s t test was used for continuous variables and Cochran’s Q test was used for categorical variables. A P-value of less than .05 was considered significant. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Results Baseline characteristics During the study period, 450 individuals underwent bicaval HT at the 2 institutions. Of these, 30 (6.7%) were initiated on terbutaline in the early post-operative period and were included in the analysis (Figure 1). Baseline characteristics stratified by use of terbutaline are shown in Table 1. Among the whole cohort, the median age at time of transplant was 56 years and 75% were male with 23% black and 18% Hispanic recipients; age, sex, race, and ethnicity did not differ between the 2 groups. The use of amiodarone pre-transplant (50% in terbutaline vs 45.5% in no terbutaline groups, P = .63) and pre-transplant inotropic (40% vs 31.7%, P = .35) and MCS (76.4% vs 71.4%, P = .54) were also similar between groups. Donor age was older in the terbutaline group (37 vs 32 years, P = .01). Although ischemic time was longer in the terbutaline group (3.9 vs 3.5 hours, P = .02), this was not clinically significant. Donor type and prevalence of sex mismatch was similar. Notably, preservation methods differed between the 2 groups with higher utilization of Organ Care System (OCS) (26.7% vs 15.2%, P = .02). Overall incidence of PGD, need for renal replacement therapy and ICU length of stays were similar between groups.Figure 1Study flow chart. PPM = permanent pacemaker; SND = sinus node dysfunction.Table 1Baseline characteristics of study cohortCharacteristicAll HT recipients (n = 450)Terbutaline (n = 30)No terbutaline (n = 420)P-valueRecipient demographicsAge at transplant, median (IQR)56.0 (44.0–63.0)57.5 (42.0–64.0)56.0 (44.5–63.0).71Male sex339 (75.3)23 (76.7)316 (75.2).86Race/ethnicity.58 White222 (49.4)19 (63.3)203 (48.5) Black102 (22.7)4 (13.3)98 (23.4) Hispanic82 (18.3)5 (16.7)77 (18.4) Asian40 (8.9)2 (6.7)38 (9.1) Other3 (0.67)0 (0)3 (0.7)Body mass index, (kg/m2)26.9 (23.4–30.5)25.8 (23.8–28.9)26.9 (23.4–30.6).46Etiology of HF.45 Non-ischemic245 (54.4)14 (46.7)231 (55.0) Ischemic104 (23.1)7 (23.3)97 (23.1) Congenital heart disease36 (8.0)2 (6.7)34 (8.1) Allograft failure/re-transplantation20 (4.4)1 (3.3)19 (4.5) Restrictive (HCM/amyloid)45 (10.0)6 (20.0)39 (9.3)History of diabetes110 (24.4)3 (10.0)107 (25.5).057Use of amiodarone pre-transplant205 (45.8)15 (50.0)190 (45.5).63Pre-transplant inotropic support145 (32.2)12 (40.0)133 (31.7).35Pre-transplant MCS323 (71.8)23 (76.7)300 (71.4).54 IABP125 (27.8)5 (16.7)120 (28.7) Microaxial flow pump72 (16.0)10 (33.3)62 (14.8) ECMO52 (11.6)5 (16.7)47 (11.2) Durable LVAD74 (16.4)3 (10.0)71 (17.0)Multi-organ transplant74 (16.4)4 (13.3)70 (16.7).80Donor demographicsIschemic time, hours3.5 (3.0–4.3)3.9 (3.3–5.2)3.5 (2.9–4.3).017Donor age32.0 (25.0–39.0)37.0 (30.0–42.0)32.0 (25.0–38.0).012Donor male sex232 (51.6)15 (50.0)217 (51.7).86Sex mismatch157 (34.9)10 (33.3)147 (35.0).85Donor type.39 DBD393 (87.9)25 (83.3)368 (88.3) DCD54 (12.1)5 (16.7)49 (11.8)Preservation method.022 Ice131 (29.1)4 (13.3)127 (30.2) Hypothermic static preservation247 (54.9)18 (60.0)229 (54.5) Organ Care System72 (16.0)8 (26.7)64 (15.2)Hospital coursePGD36 (8.0)2 (6.7)34 (8.1)1.0Need for CRRT80 (17.8)7 (23.3)73 (17.4).46ICU length of stay, days7.0 (5.0–12.0)9.5 (8.0–16.0)7.0 (5.0–12.0).065CRRT = continuous renal replacement therapy; DBD = donation after brain death; DCD = donation after circulatory death; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate, HF = heart failure; IABP = intra-aortic balloon pump; ICU = intensive care unit; LVAD = left ventricular assist device, MCS = mechanical circulatory support; PGD = primary graft dysfunction. Study flow chart. PPM = permanent pacemaker; SND = sinus node dysfunction. Table 1Baseline characteristics of study cohortCharacteristicAll HT recipients (n = 450)Terbutaline (n = 30)No terbutaline (n = 420)P-valueRecipient demographicsAge at transplant, median (IQR)56.0 (44.0–63.0)57.5 (42.0–64.0)56.0 (44.5–63.0).71Male sex339 (75.3)23 (76.7)316 (75.2).86Race/ethnicity.58 White222 (49.4)19 (63.3)203 (48.5) Black102 (22.7)4 (13.3)98 (23.4) Hispanic82 (18.3)5 (16.7)77 (18.4) Asian40 (8.9)2 (6.7)38 (9.1) Other3 (0.67)0 (0)3 (0.7)Body mass index, (kg/m2)26.9 (23.4–30.5)25.8 (23.8–28.9)26.9 (23.4–30.6).46Etiology of HF.45 Non-ischemic245 (54.4)14 (46.7)231 (55.0) Ischemic104 (23.1)7 (23.3)97 (23.1) Congenital heart disease36 (8.0)2 (6.7)34 (8.1) Allograft failure/re-transplantation20 (4.4)1 (3.3)19 (4.5) Restrictive (HCM/amyloid)45 (10.0)6 (20.0)39 (9.3)History of diabetes110 (24.4)3 (10.0)107 (25.5).057Use of amiodarone pre-transplant205 (45.8)15 (50.0)190 (45.5).63Pre-transplant inotropic support145 (32.2)12 (40.0)133 (31.7).35Pre-transplant MCS323 (71.8)23 (76.7)300 (71.4).54 IABP125 (27.8)5 (16.7)120 (28.7) Microaxial flow pump72 (16.0)10 (33.3)62 (14.8) ECMO52 (11.6)5 (16.7)47 (11.2) Durable LVAD74 (16.4)3 (10.0)71 (17.0)Multi-organ transplant74 (16.4)4 (13.3)70 (16.7).80Donor demographicsIschemic time, hours3.5 (3.0–4.3)3.9 (3.3–5.2)3.5 (2.9–4.3).017Donor age32.0 (25.0–39.0)37.0 (30.0–42.0)32.0 (25.0–38.0).012Donor male sex232 (51.6)15 (50.0)217 (51.7).86Sex mismatch157 (34.9)10 (33.3)147 (35.0).85Donor type.39 DBD393 (87.9)25 (83.3)368 (88.3) DCD54 (12.1)5 (16.7)49 (11.8)Preservation method.022 Ice131 (29.1)4 (13.3)127 (30.2) Hypothermic static preservation247 (54.9)18 (60.0)229 (54.5) Organ Care System72 (16.0)8 (26.7)64 (15.2)Hospital coursePGD36 (8.0)2 (6.7)34 (8.1)1.0Need for CRRT80 (17.8)7 (23.3)73 (17.4).46ICU length of stay, days7.0 (5.0–12.0)9.5 (8.0–16.0)7.0 (5.0–12.0).065CRRT = continuous renal replacement therapy; DBD = donation after brain death; DCD = donation after circulatory death; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate, HF = heart failure; IABP = intra-aortic balloon pump; ICU = intensive care unit; LVAD = left ventricular assist device, MCS = mechanical circulatory support; PGD = primary graft dysfunction. Baseline characteristics of study cohort CRRT = continuous renal replacement therapy; DBD = donation after brain death; DCD = donation after circulatory death; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate, HF = heart failure; IABP = intra-aortic balloon pump; ICU = intensive care unit; LVAD = left ventricular assist device, MCS = mechanical circulatory support; PGD = primary graft dysfunction. Terbutaline initiation Terbutaline was initiated an average of 6.5 days (IQR 5.3, 10.0) post-transplant (Table 2). Approximately half (n = 14) were on inotropes at the time of initiation. Type and average dose of inotropes at the time of terbutaline start are described in Supplemental Table 1. Median HR prior to drug initiation was 72 bpm (IQR 64–76). The most common starting dose was 2.5 mg twice per day (TID) (n = 12, 40%) although 30% (n = 9) of patients were started at 5 mg TID (Table 2). Maximum dose titration was variable with 23% (n = 7) reaching 10 mg TID, 13% (n = 4) reaching 7.5 mg TID and 30% (n = 9) on 5 mg TID. 60% (n = 18) required treatment for hyperkalemia while on the medication.Table 2Terbutaline initiation and tolerabilityCharacteristicN (%)Median time from transplant to terbutaline initiation, days6.5 (5.3–10)Median time on drug, days8 (4–22)Starting dose 2.5 mg BID8 (27) 2.5 mg TID12 (40) 5 mg BID1 (3) 5 mg TID9 (30)Maximum dose 2.5 mg BID3 (10) 2.5 mg TID4 (13) 5 mg BID3 (10) 5 mg TID9 (30) 7.5 mg TID4 (13) 10 mg TID7 (23)Reason for stopping Improvement in HR14 (47) No improvement in HR7 (23) Tremors3 (10) Arrythmias4 (13) Death/cardiac arrest2 (7)Treatment for hyperkalemia while on drug18 (60)Need for PPM2 (7)BID = twice a day; HR = heart rate; PPM = permanent pacemaker; TID = 3 times a day. Table 2Terbutaline initiation and tolerabilityCharacteristicN (%)Median time from transplant to terbutaline initiation, days6.5 (5.3–10)Median time on drug, days8 (4–22)Starting dose 2.5 mg BID8 (27) 2.5 mg TID12 (40) 5 mg BID1 (3) 5 mg TID9 (30)Maximum dose 2.5 mg BID3 (10) 2.5 mg TID4 (13) 5 mg BID3 (10) 5 mg TID9 (30) 7.5 mg TID4 (13) 10 mg TID7 (23)Reason for stopping Improvement in HR14 (47) No improvement in HR7 (23) Tremors3 (10) Arrythmias4 (13) Death/cardiac arrest2 (7)Treatment for hyperkalemia while on drug18 (60)Need for PPM2 (7)BID = twice a day; HR = heart rate; PPM = permanent pacemaker; TID = 3 times a day. Terbutaline initiation and tolerability BID = twice a day; HR = heart rate; PPM = permanent pacemaker; TID = 3 times a day. Terbutaline discontinuation Median duration of terbutaline was 8 days (IQR 4–22). Median HR at discontinuation was 91 bpm, significantly higher than HR prior to initiation (91 vs 72 bpm, P < .001, Table 3). Changes in HR were overall similar when stratified by inotrope use at the time of terbutaline initiation (Supplemental Table 2). Compared with prior to drug initiation, cardiac index by Fick was significantly higher at time of terbutaline discontinuation (3.65 vs 2.95, P = .001) with no significant differences in RA pressure or PA pressures (Table 3).Table 3Hemodynamic and laboratory parameters pre- and post-terbutalineCharacteristicPre-terbutalinePost-terbutalineP-valueMedian HR∗72 (64–76)91 (77–97)<.001RA pressure, mm Hg, median†10.5 (8.5–13.0)10.5 (6.5–13.0).93Systolic PA pressure, mm Hg, median†35.0 (29.0–40.5)34.5 (30.0–46.5).35Mean PA pressure, mm Hg, median†22.0 (18.5–28.0)23.5 (19.0–26.5).95Fick cardiac index†2.95 (2.65–3.20)3.65 (3.23–3.86).001eGFR,‡mL/min/1.73 m2.63 <304 (13.3)3 (10.0) 30–595 (16.7)8 (26.7) 60–897 (23.3)8 (26.7) >9014 (46.7)11 (36.7)Potassium, mmol/L§4.6 (4.15–4.95)4.8 (4.4–5.0).85Results are represented in median and interquartile range; Testing: paired student t test for continuous, Cochran’s Q test for categorical.eGFR = estimated glomerular filtration rate; HR = heart rate; PA = pulmonary artery; RA = right atrial.∗Includes 29 patients with both pre and post data.†Includes 20 patients with both pre and post data.‡includes 30 patients with both pre and post data.§includes 28 patients with both pre and post data. Table 3Hemodynamic and laboratory parameters pre- and post-terbutalineCharacteristicPre-terbutalinePost-terbutalineP-valueMedian HR∗72 (64–76)91 (77–97)<.001RA pressure, mm Hg, median†10.5 (8.5–13.0)10.5 (6.5–13.0).93Systolic PA pressure, mm Hg, median†35.0 (29.0–40.5)34.5 (30.0–46.5).35Mean PA pressure, mm Hg, median†22.0 (18.5–28.0)23.5 (19.0–26.5).95Fick cardiac index†2.95 (2.65–3.20)3.65 (3.23–3.86).001eGFR,‡mL/min/1.73 m2.63 <304 (13.3)3 (10.0) 30–595 (16.7)8 (26.7) 60–897 (23.3)8 (26.7) >9014 (46.7)11 (36.7)Potassium, mmol/L§4.6 (4.15–4.95)4.8 (4.4–5.0).85Results are represented in median and interquartile range; Testing: paired student t test for continuous, Cochran’s Q test for categorical.eGFR = estimated glomerular filtration rate; HR = heart rate; PA = pulmonary artery; RA = right atrial.∗Includes 29 patients with both pre and post data.†Includes 20 patients with both pre and post data.‡includes 30 patients with both pre and post data.§includes 28 patients with both pre and post data. Hemodynamic and laboratory parameters pre- and post-terbutaline Results are represented in median and interquartile range; Testing: paired student t test for continuous, Cochran’s Q test for categorical. eGFR = estimated glomerular filtration rate; HR = heart rate; PA = pulmonary artery; RA = right atrial. Includes 29 patients with both pre and post data. Includes 20 patients with both pre and post data. includes 30 patients with both pre and post data. includes 28 patients with both pre and post data. The most common reason for discontinuation was improvement in HR (n = 14, 47%, Table 2). 13% of patients (n = 4) experienced arrhythmias leading to discontinuation (atrial fibrillation in 2 cases, supraventricular tachycardia in 1 case and ventricular tachycardia in 1 case). 10% (n = 3) had tremors which were the reason for discontinuation. Terbutaline responders 26 patients had HR data available at day 0 and day 3 (non-pacer dependent). 10 patients (38%) met criteria for terbutaline response. Percent change in HR after day 3 of terbutaline is shown in Figure 2. Median percentage change in HR was 8.6 bpm. Average HR trends at baseline, day 3, drug stop, and 1 month post-terbutaline among responders and non-responders are included in Supplemental Table 3.Figure 2Percent change in HR from day 0 to day 3 of terbutaline. Percent change in HR after terbutaline initiation is shown per individual (n = 26). Four patients were still predominantly paced at day 3 so unable to determine change in HR. HR = heart rate. Percent change in HR from day 0 to day 3 of terbutaline. Percent change in HR after terbutaline initiation is shown per individual (n = 26). Four patients were still predominantly paced at day 3 so unable to determine change in HR. HR = heart rate. Characteristics were compared between terbutaline responders and non-responders (Table 4). There were no significant differences in demographics, pre-transplant temporary MCS, donor characteristics, operative characteristics, or early post-transplant complications between the 2 groups. 63% of non-responders were on concurrent inotropes at the time of terbutaline initiation compared with 10% of responders (P = 0.01). Use of amiodarone pre-transplant was similar between responders and non-responders. Additionally, there were no differences in starting doses, maximum doses, potassium levels, or renal function between groups.Table 4Baseline characteristics of terbutaline responders and non-respondersTerbutaline responders∗ (n = 10)Terbutaline non-responder (n = 16)P-valueRecipient demographicsAge at transplant, median (IQR)53.5 (43.0–64.0)62.0 (52.5–65.0).48Male sex1 (10.0)4 (25.0).62Race/ethnicity White6 (60.0)12 (75.0).13 Black0 (0)3 (18.8) Hispanic2 (20.0)0 (0) Asian2 (20.0)1 (6.3)Etiology of HF Non-ischemic3 (30.0)9 (56.3).13 Ischemic2 (20.0)4 (25.0) Congenital heart disease2 (20.0)0 (0) Allograft failure/re-transplantation2 (20.0)0 (0) Restrictive (HCM/amyloid)1 (10.0)3 (18.8)History of diabetes0 (0)5 (31.3).12Use of amiodarone pre-transplant5 (50.0)11 (68.8).43Pre-transplant inotropic support6 (60.0)6 (37.5).42Pre-transplant MCS.018 IABP2 (20.0)2 (12.5) Microaxial flow pump2 (20.0)5 (31.2) ECMO1 (10.0)3 (18.8) Durable LVAD0 (0)5 (31.3)Multi-organ transplant3 (30.0)1 (6.3).26Donor characteristicsIschemic time, hours, median (IQR)3.5 (2.9–3.6)3.7 (2.5–4.3).56Donor age, median (IQR)39.0 (33.0–45.0)37.0 (29.0–43.0).73Donor male sex5 (50.0)7 (43.8)1.0Sex mismatch4 (40.0)5 (31.3).69Donor Type DBD9 (90.0)12 (75.0).62 DCD1 (10.0)4 (25.0)Preservation method.49 Ice8 (80.0)12 (75.0) Hypothermic static preservation1 (10.0)0 (0) Organ care system1 (10.0)4 (25.0)Hospital courseInotrope of day 0 of terbutaline1 (10.0)10 (62.5).014PGD0 (0)2 (12.5).51Need for CRRT3 (30.0)3 (18.8).64ICU length of stay, days, median (IQR)8.0 (5.0–11.0)8.5 (6.0–18.0).42Terbutaline CharacteristicsStarting dose 2.5 mg BID2 (20.0)4 (25.0).22 2.5 mg TID3 (30.0)9 (56.2) 5 mg BID1 (10.0)0 (0) 5 mg TID4 (40.0)3 (18.8)Maximum dose 2.5 mg BID1 (10.0)2 (12.5).50 2.5 mg TID2 (20.0)2 (12.5) 5 mg BID1 (10.0)1 (6.3) 5 mg TID4 (40.0)4 (25.0) 7.5 mg TID2 (20.0)2 (12.5) 10 mg TID0 (0)5 (31.3)Potassium level pre-drug, mmol/L, median (IQR)4.75 (4.65–5.5)4.5 (4.1–4.95).091eGFR pre-drug, mL/min/1.73 m2 <303 (30.0)1 (6.3).48 30–591 (10.0)4 (25.0) 60–892 (20.0)4 (25.0) >904 (40.0)7 (43.8)Potassium level post-drug, mmol/L, median (IQR)4.7 (4.0–5.4)4.8 (4.65–5.0).69eGFR post-drug, mL/min/1.73 m2 <302 (20.0)1 (6.3).84 30–593 (30.0)5 (31.3) 60–892 (20.0)4 (25.0) >903 (30.0)6 (37.5)BID = twice a day; CRRT = continuous renal replacement therapy; DBD = donation after brain death; DCD = donation after circulatory death; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate, HF = heart failure; IABP = intra-aortic balloon pump; ICU = intensive care unit; IQR = interquartile range; LVAD = left ventricular assist device, MCS = mechanical circulatory support; PGD = primary graft dysfunction; TID = 3 times a day.∗Response was defined as increase in HR of at least 15 bpm by day 3 of terbutaline. Table 4Baseline characteristics of terbutaline responders and non-respondersTerbutaline responders∗ (n = 10)Terbutaline non-responder (n = 16)P-valueRecipient demographicsAge at transplant, median (IQR)53.5 (43.0–64.0)62.0 (52.5–65.0).48Male sex1 (10.0)4 (25.0).62Race/ethnicity White6 (60.0)12 (75.0).13 Black0 (0)3 (18.8) Hispanic2 (20.0)0 (0) Asian2 (20.0)1 (6.3)Etiology of HF Non-ischemic3 (30.0)9 (56.3).13 Ischemic2 (20.0)4 (25.0) Congenital heart disease2 (20.0)0 (0) Allograft failure/re-transplantation2 (20.0)0 (0) Restrictive (HCM/amyloid)1 (10.0)3 (18.8)History of diabetes0 (0)5 (31.3).12Use of amiodarone pre-transplant5 (50.0)11 (68.8).43Pre-transplant inotropic support6 (60.0)6 (37.5).42Pre-transplant MCS.018 IABP2 (20.0)2 (12.5) Microaxial flow pump2 (20.0)5 (31.2) ECMO1 (10.0)3 (18.8) Durable LVAD0 (0)5 (31.3)Multi-organ transplant3 (30.0)1 (6.3).26Donor characteristicsIschemic time, hours, median (IQR)3.5 (2.9–3.6)3.7 (2.5–4.3).56Donor age, median (IQR)39.0 (33.0–45.0)37.0 (29.0–43.0).73Donor male sex5 (50.0)7 (43.8)1.0Sex mismatch4 (40.0)5 (31.3).69Donor Type DBD9 (90.0)12 (75.0).62 DCD1 (10.0)4 (25.0)Preservation method.49 Ice8 (80.0)12 (75.0) Hypothermic static preservation1 (10.0)0 (0) Organ care system1 (10.0)4 (25.0)Hospital courseInotrope of day 0 of terbutaline1 (10.0)10 (62.5).014PGD0 (0)2 (12.5).51Need for CRRT3 (30.0)3 (18.8).64ICU length of stay, days, median (IQR)8.0 (5.0–11.0)8.5 (6.0–18.0).42Terbutaline CharacteristicsStarting dose 2.5 mg BID2 (20.0)4 (25.0).22 2.5 mg TID3 (30.0)9 (56.2) 5 mg BID1 (10.0)0 (0) 5 mg TID4 (40.0)3 (18.8)Maximum dose 2.5 mg BID1 (10.0)2 (12.5).50 2.5 mg TID2 (20.0)2 (12.5) 5 mg BID1 (10.0)1 (6.3) 5 mg TID4 (40.0)4 (25.0) 7.5 mg TID2 (20.0)2 (12.5) 10 mg TID0 (0)5 (31.3)Potassium level pre-drug, mmol/L, median (IQR)4.75 (4.65–5.5)4.5 (4.1–4.95).091eGFR pre-drug, mL/min/1.73 m2 <303 (30.0)1 (6.3).48 30–591 (10.0)4 (25.0) 60–892 (20.0)4 (25.0) >904 (40.0)7 (43.8)Potassium level post-drug, mmol/L, median (IQR)4.7 (4.0–5.4)4.8 (4.65–5.0).69eGFR post-drug, mL/min/1.73 m2 <302 (20.0)1 (6.3).84 30–593 (30.0)5 (31.3) 60–892 (20.0)4 (25.0) >903 (30.0)6 (37.5)BID = twice a day; CRRT = continuous renal replacement therapy; DBD = donation after brain death; DCD = donation after circulatory death; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate, HF = heart failure; IABP = intra-aortic balloon pump; ICU = intensive care unit; IQR = interquartile range; LVAD = left ventricular assist device, MCS = mechanical circulatory support; PGD = primary graft dysfunction; TID = 3 times a day.∗Response was defined as increase in HR of at least 15 bpm by day 3 of terbutaline. Baseline characteristics of terbutaline responders and non-responders BID = twice a day; CRRT = continuous renal replacement therapy; DBD = donation after brain death; DCD = donation after circulatory death; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate, HF = heart failure; IABP = intra-aortic balloon pump; ICU = intensive care unit; IQR = interquartile range; LVAD = left ventricular assist device, MCS = mechanical circulatory support; PGD = primary graft dysfunction; TID = 3 times a day. Response was defined as increase in HR of at least 15 bpm by day 3 of terbutaline. Sinus node recovery 50% of those prescribed terbutaline were defined as meeting criteria for sinus node recovery. Among the 16 non-responders to terbutaline, 50% (n = 8) met criteria for sinus node recovery. Percent change in HR from pre-drug to time of discontinuation is shown in Figure 3, depicting significant variability among individuals. Median percentage change in HR was 19.4%. 4 individuals had a decrease in HR. Baseline characteristics of those with sinus node recovery vs those who did not have sinus node recovery were largely similar (Supplemental Table 4).Figure 3Change in HR from pre-drug to time of terbutaline discontinuation. Percent change in HR from prior to drug initiation to time of terbutaline discontinuation is shown per individual (n = 29). One patient who did not have an underlying rhythm at the time of initiation was excluded from this analysis. HR = heart rate. Change in HR from pre-drug to time of terbutaline discontinuation. Percent change in HR from prior to drug initiation to time of terbutaline discontinuation is shown per individual (n = 29). One patient who did not have an underlying rhythm at the time of initiation was excluded from this analysis. HR = heart rate. Need for permanent pacing 2 patients needed a PPM. For the first patient, terbutaline had been stopped on day 10 post-HT because of atrial fibrillation. Although off terbutaline, he was resumed on intravenous dobutamine for intermittent junctional rhythm and sinus bradycardia in the 60s. Ultimately, he underwent PPM at 33 days post-HT. The second patient developed 2:1 atrioventricular block in setting of trifascicular block on day 43 post-HT and was recommended to undergo dual chamber PPM while hospitalized, however, he declined. He was treated empirically with corticosteroids for rejection and continued on terbutaline as an outpatient. Subsequent rhythm monitoring showed no further high-degree heart block. However, given persistent sinus bradycardia in the 50s on terbutaline, he underwent PPM implantation 400 days post-transplant. 2 patients died during the follow-up period (1 at 29 days and 1 at 30 days post-HT). However, both patients who died had sinus node recovery, with 1 patient being weaned off terbutaline before date of death. Discussion In the current study, we sought to evaluate characteristics of patients requiring terbutaline in the early post-transplant period for SND and their hemodynamic and clinical changes. Our main findings are the following: (1) Of 450 patients transplanted during the study period, 7% required initiation of terbutaline; (2) patients initiated on terbutaline had older donor age and different organ preservation and transport methods; (3) Among those started on terbutaline, there was a significant increase in HR and Fick cardiac index after treatment initiation although changes in HR varied widely from individual to individual; (4) 50% of those initiated on terbutaline had sinus node recovery and 2 patients required permanent pacemaker implantation. Taken together our findings suggest that despite individual variability in HR response with terbutaline and sinus node recovery, ultimate need for PPM remained low even among those without significant increase in HR. In our contemporary population of bicaval HT, <10% of recipients over the study period required initiation of terbutaline in the early post-operative period. By contrast, another single center experience reported that 64% of their HT recipients (229/357) from 2016 to 2022 required terbutaline during their index admission.8 In their cohort, bicaval anastomosis was used in 97% and 71% had prior amiodarone exposure. Ultimately 9% of patients received PPM placement at median of 24 days from transplant. Notably, this study did not compare characteristics of other HT recipients during the study period who did not require terbutaline. In our study, patients initiated on terbutaline had longer ischemic times, older donor age and different organ preservation and transport methods as compared with HT recipients who did not require terbutaline. There were no differences in pre-transplant amiodarone exposure between groups. It has been previously demonstrated that older donor age and prolonged ischemic time have been associated with SND after HT, and these have also been reported as risk factors for early PPM implantation.1,7 There was an increase in the use of OCS for preservation in the terbutaline group. The higher perfusion flows with OCS can be associated with myocardial edema which may impair contractility of the heart and have contributed to transient SND. One unique aspect of our study was the incorporation of changes in invasive hemodynamics and laboratory parameters as measured before and after drug initiation. Post-transplant SND leading to bradycardia can reduce cardiac output as a denervated heart cannot increase its HR during exercise. In addition to a significant increase in HR, cardiac indices as measured by Fick significantly increased after initiation of terbutaline. In the early post-operative setting where stroke volumes are typically fixed because of diastolic dysfunction of the heart allografts, changes in HR may have increased relative importance. As terbutaline is largely eliminated by the kidney and can also induce hypokalemia through activation of the sodium-potassium ATPase and influx of potassium intracellularly,11 renal function and potassium levels were collected pre- and post. We did not find any significant decreases in potassium levels after drug initiation and 60% of those on terbutaline required treatment for hyperkalemia. This is likely because of concomitant use of calcineurin inhibitors and prophylactic trimethoprim-sulfamethoxazole in this population in which hyperkalemia is often observed.12 Sinus node recovery was defined as those who achieved a HR of ≥90 bpm. As the heart is completely denervated after HT, the HR will approach the intrinsic HR which is defined as 112 – (0.46 x donor age in years).13 Therefore, relative bradycardia in the HT population is often defined as a HR below 90 bpm.8 Our previously published institutional protocol set a goal HR of ≥90 bpm after initiation of terbutaline in line with these data.7 At the individual level, there was significant variability with respect to percent change in HR after drug initiation. 50% of those initiated on terbutaline were classified as having sinus node recovery. However, the drug was stopped in 23% because of lack of improvement in HR despite dose escalation. However, these patients were still able to maintain end-organ function and cardiac output such that only 2 patients ultimately required PPM. Avoiding unnecessary device implantation may help to reduce risks of complications particularly in the early post-operative period when immunosuppressive regimens are the most intensive and wound healing may be significantly impaired.7 Comparison of baseline characteristics between terbutaline responders and non-responders were relatively similar as were patients with and without sinus node recovery. We recognize that our study is not without limitations. This is a small 2-center cohort study and therefore, our findings may not be generalizable. Furthermore, initiation of terbutaline was provider-driven allowing for some variability with respect to who received and who did not receive the drug. As such, there may be patients with low HRs who did not receive terbutaline and were not included in this study. Furthermore, there was no comparison group of heart transplant recipients with low HR who did not receive terbutaline. Although the rate of PPM was low, we recognize that terbutaline alone may not have affected PPM implant and other factors, including inotropes, individual characteristics and unmeasured confounders may have contributed to this finding. We focused specifically on terbutaline for the current analysis as this is the most commonly used medication at our institution for early SND and therefore did not assess utilization of isoproterenol or theophylline. Lastly, given limited data, definitions of terbutaline response were extrapolated from animal studies. Conclusion Despite significant variability from individual-to-individual, terbutaline may help to delay or avoid PPM for early SND after HT. Although data suggest aiming for a goal HR of ≥90 bpm on terbutaline therapy, HT recipients may be able to maintain appropriate cardiac output with lower HR off pharmacologic therapy and still avoid PPM. More data are needed regarding predictors and factors affecting individual-level response. Disclosures EMD serves on a clinical trial committee for Abiomed. EYW has been a consultant for Boston Scientific, Medtronic, Abbott, Sanofi, and Cardiologs. The remaining authors have nothing to disclose.